Takeda Prices Oral Multiple Myeloma Follow-On Ninlaro On Par With Velcade
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of the next-generation proteasome inhibitor ixazomib will pave the way for an all-oral combination with Revlimid and dexamethasone and give Takeda an opportunity to extend its oncology franchise beyond Velcade, which could see generic competition in late 2017.
You may also be interested in...
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.